Altimmune, Inc. (ALT)

Market Cap	313.88M
Revenue (ttm)	20,000
Net Income (ttm)	-90.24M
Shares Out	81.11M
EPS (ttm)	-1.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,058,836
Open	3.415
Previous Close	3.500
Day's Range	3.300 - 4.040
52-Week Range	2.900 - 11.160
Beta	0.57
Analysts	Strong Buy
Price Target	20.20 (+421.96%)
Earnings Date	Aug 7, 2025

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: ALT
• Website: https://altimmune.com

Financial Performance

In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price forecast is $20.2, which is an increase of 421.96% from the latest price.

Price Target

$20.2

(421.96% upside)

Analyst Consensus: Strong Buy